Stifel Maintains Hold on RxSight, Lowers Price Target to $7
Stifel analyst Tom Stephan maintains RxSight (NASDAQ:RXST) with a Hold and lowers the price target from $8 to $7.
Stocks · News reference
RxSight Sees Q2 Revenue Of $32M-$34M; Sees FY2026 Revenue Of $140M-$160M
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
UBS Maintains Neutral on RxSight, Raises Price Target to $6.3
UBS analyst Patrick Wood maintains RxSight (NASDAQ:RXST) with a Neutral and raises the price target from $5.5 to $6.3.
RxSight Q2 Adj. EPS $(0.11) Beats $(0.33) Estimate, Sales $33.741M Beat $32.547M Estimate
8-K filing — RxSight, Inc. (RXST)
Filed: 2026-07-15 AccNo: 0001193125-26-304812 Size: 186 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits